Impacts of CMS’ GLP-1 pilot program begin to take shape
Friday, August 28 – Nearly two months into a federal pilot program aimed at expanding access to weight loss drugs for seniors, uptake data and reported benefits are beginning to materialize.
The latest findings,
Fighting childhood obesity: Researchers study semaglutide with adolescents
Saturday, August 29 – Kentucky has one of the highest childhood obesity rates in the country, and the health consequences carry forward throughout life. That’s one of the reasons researchers at the University of Kentucky are leading a groundbreaking clinical trial to determine whether medical intervention can reverse the early signs of heart disease in children struggling with severe obesity.
Can GLP-1s really help treat PMOS? Experts answer 3 key questions
Thursday, August 27 – Can GLP-1s really help treate PMOS (Polyendocrine Metabolic Ovarian Syndrome)? Experts answer 3 key questions.
GLP-1 Drugs Could Help Narrow Lifespan Gap in Serious Mental Illness
Saturday, August 29 – (MedPage Today) — Starting a GLP-1 receptor agonist was associated with significantly lower risks of death and cardiovascular events in adults with serious mental illness (SMI), a target trial emulation showed.
Among 195,184 propensity score…
GLP-1s May Offer Benefit in Ulcerative Colitis, Real-World Data Suggest
Saturday, August 29 – (MedPage Today) — The use of GLP-1 receptor agonists was linked to improved remission rates in patients with ulcerative colitis, a retrospective cohort study suggested.
Among 300 patients with ulcerative colitis, use of liraglutide (Victoza…
The Medicare GLP-1 discount has one big catch: Some sick patients don’t qualify
Saturday, August 29 – About 1 in 5 American adults have taken a GLP-1 medication, and most of them, including those with health insurance, say the drugs are difficult to afford. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss, which is why the Medicare GLP-1 Bridge program made a big splash when it launched in July.
Dolly Parton’s Cause of Death; 14 Newborns Killed in Hospital Fire; GLP-1 Coverage
Saturday, August 29 – (MedPage Today) — Note that some links may require registration or subscription.
Country music superstar Dolly Parton, 80, died Tuesday after a brief battle with an undisclosed type of cancer, according to her family. She had also been dealing…
GLP-1 meds prompt rethink of obesity and eating disorder care
Saturday, August 29 – Obesity and eating disorders have traditionally been treated as separate areas of health care—but the rapid rise of GLP-1 medicines is increasingly bringing the two together. Adelaide University researchers say the growing use of medicines such as Ozempic and Mounjaro is highlighting an underrecognized overlap between the conditions—and raising important questions about who could benefit and who may be at risk.
‘Gray Market’ Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings
Wednesday, August 26 – (MedPage Today) — People who took “gray market” compounded retatrutide, an investigational triple hormone receptor agonist, achieved less weight loss with up to 12 months of treatment than clinical trial participants, a preprint study suggested…
Pharmacy Asks Court To Toss Novo Nordisk Semaglutide Suit
Wednesday, August 26 – A pharmacy asked a Texas federal judge to toss claims brought by Novo Nordisk Inc. accusing the pharmacy of illicitly compounding a lucrative weight-loss drug called semaglutide, saying Novo Nordisk’s complaint amounts to a grievance list against the compounding industry.